TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Clinical trial NCT02764333 · COMPLETED
Trial details
- NCT number
- NCT02764333
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-06
- Primary completion
- 2021-01-20
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.